CRISPR-Cas9 is an RNA-guided DNA-cutting enzyme system that allows researchers to modify the genetic code of virtually any organism with a precision, speed, and affordability previously unattainable.

Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...

IDT played a pivotal role in manufacturing the personalized gene editing therapy given to baby KJ Muldoon to treat his rare ...

Dr Giovanni Pietrogrande and Dr Tahmina Tabassum developed their new fusion protein at UQ's Australian Institute for ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

Scientists are refining electroporation methods to improve CRISPR/Cas9 gene editing efficiency while preserving cell health. By adjusting buffer composition, pulse parameters, and delivery formats, ...

Intellia Therapeutics (NTLA) is a clinical-stage biotech firm working on CRISPR-based treatments that try to edit genes ...

Sidra Medicine, a member of Qatar Foundation, has been qualified by Vertex Pharmaceuticals as one of a of a limited number of ...

Clustered regularly interspaced short palindromic repeats (CRISPR) refer to the small fragments of viral DNA that are stored by the bacteria as a part of their defense mechanism. CRISPR–Cas9 is a ...